Overview

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gilead Sciences
Immunomedics, Inc.
Treatments:
Antibodies
Veltuzumab